Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches
The management of TNENs requires a multidisciplinary and individualized approach based on histologic subtype, somatostatin receptor status, and disease aggressiveness. Despite promising therapeutic options, robust prospective data remain limited. The integration of TNENs into basket trials, the molecular refinement of prognostic subgroups (e.g., NET G3), and the conduct of dedicated multicenter prospective studies are urgently needed to define optimal treatment algorithms and improve clinical outcomes in these rare entities.
Authors
- Pietro De Placido (ORCID: https://orcid.org/0000-0002-1979-5400)
- Noura J. Choudhury (ORCID: https://orcid.org/0000-0002-5980-4973)
- Roberto Bianco (ORCID: https://orcid.org/0000-0003-3311-260X)
- Christine M. Bestvina (ORCID: https://orcid.org/0000-0001-7189-1590)
- A. Esposito (ORCID: https://orcid.org/0000-0003-0664-3122)
- Waqas Haque (ORCID: https://orcid.org/0000-0001-6754-7658)
- Erica Pietroluongo (ORCID: https://orcid.org/0000-0003-2370-2139)
- Anna Di Lello
- Marina Chiara Garassino
- Rachel Brattin
Institutions
- Vita-Salute San Raffaele University (IT)
- University of Chicago (US)
- Federico II University Hospital (IT)
- Dana-Farber Cancer Institute (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University of Naples Federico II (IT)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100935
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00